ATE197403T1 - Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase- peptidantigenen exprimierenden zellen - Google Patents

Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase- peptidantigenen exprimierenden zellen

Info

Publication number
ATE197403T1
ATE197403T1 AT94905393T AT94905393T ATE197403T1 AT E197403 T1 ATE197403 T1 AT E197403T1 AT 94905393 T AT94905393 T AT 94905393T AT 94905393 T AT94905393 T AT 94905393T AT E197403 T1 ATE197403 T1 AT E197403T1
Authority
AT
Austria
Prior art keywords
detecting
abnormal cells
methods
cells expressing
peptide antigens
Prior art date
Application number
AT94905393T
Other languages
English (en)
Inventor
Thierry Boon-Falleur
Vincent Brichard
Pel Aline Van
Plaen Etienne De
Pierre Coulie
Jean-Christophe Renauld
Thomas Woelfel
Bernard Lethe
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/081,673 external-priority patent/US5487974A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE197403T1 publication Critical patent/ATE197403T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18001—Tyrosinase (1.14.18.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
AT94905393T 1992-12-22 1993-12-14 Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase- peptidantigenen exprimierenden zellen ATE197403T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99492892A 1992-12-22 1992-12-22
US5471493A 1993-04-28 1993-04-28
US08/081,673 US5487974A (en) 1992-12-22 1993-06-23 Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
PCT/US1993/012200 WO1994014459A1 (en) 1992-12-22 1993-12-14 Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/tyrosinase peptide antigens

Publications (1)

Publication Number Publication Date
ATE197403T1 true ATE197403T1 (de) 2000-11-11

Family

ID=26733390

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99204249T ATE215830T1 (de) 1992-12-22 1993-12-14 Verfahren zur detektion und behandlung von individuen mit abnormal hla-a2/tyrosinase- peptidantigenen exprimierenden zellen
AT94905393T ATE197403T1 (de) 1992-12-22 1993-12-14 Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase- peptidantigenen exprimierenden zellen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99204249T ATE215830T1 (de) 1992-12-22 1993-12-14 Verfahren zur detektion und behandlung von individuen mit abnormal hla-a2/tyrosinase- peptidantigenen exprimierenden zellen

Country Status (16)

Country Link
US (2) US6284476B1 (de)
EP (1) EP0687180B1 (de)
JP (1) JPH08506100A (de)
CN (1) CN1059466C (de)
AT (2) ATE215830T1 (de)
AU (1) AU679965B2 (de)
CA (1) CA2152266C (de)
DE (2) DE69331813T4 (de)
DK (2) DK0687180T3 (de)
ES (2) ES2172287T4 (de)
FI (1) FI953093L (de)
GR (1) GR3035152T3 (de)
NO (1) NO952385L (de)
NZ (1) NZ259985A (de)
PT (2) PT687180E (de)
WO (1) WO1994014459A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
US7501501B2 (en) 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
US7019112B1 (en) 1996-03-19 2006-03-28 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor
WO1997034613A1 (en) * 1996-03-19 1997-09-25 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor
JP2001503966A (ja) * 1996-06-25 2001-03-27 ザ ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 脳グリコーゲンホスホリラーゼ癌抗原
AU735459B2 (en) * 1997-01-30 2001-07-12 University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
AU2003303082B2 (en) 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
AU2005326758B2 (en) 2004-06-23 2011-07-14 Board Of Regents Of The University Of Texas System Methods and compositions for the detection of biological molecules using a two particle complex
WO2015134860A1 (en) * 2014-03-07 2015-09-11 Ticona Llc Sintered polymeric particles having narrow particle size distribution for porous structures

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898814A (en) * 1986-10-06 1990-02-06 Donald Guthrie Foundation For Medical Research, Inc. A cDNA clone for human tyrosinase
WO1990012869A1 (en) * 1989-04-26 1990-11-01 Sloan-Kettering Institute For Cancer Research Non-melanocytic, eucaryotic cell constitutively expressing biologically active human tyrosinase and use thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5519117A (en) 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof

Also Published As

Publication number Publication date
JPH08506100A (ja) 1996-07-02
FI953093A0 (fi) 1995-06-21
DE69331813T2 (de) 2002-11-28
US20020128200A1 (en) 2002-09-12
PT687180E (pt) 2001-04-30
ES2172287T3 (es) 2002-09-16
WO1994014459A1 (en) 1994-07-07
NO952385L (no) 1995-06-22
DK0687180T3 (da) 2000-11-27
FI953093A7 (fi) 1995-06-21
GR3035152T3 (en) 2001-04-30
EP0687180B1 (de) 2000-11-08
NO952385D0 (no) 1995-06-16
CA2152266C (en) 2002-06-11
AU679965B2 (en) 1997-07-17
US6284476B1 (en) 2001-09-04
CN1059466C (zh) 2000-12-13
ATE215830T1 (de) 2002-04-15
NZ259985A (en) 1996-04-26
DE69329656D1 (de) 2000-12-14
DE69329656T2 (de) 2001-06-28
EP0687180A1 (de) 1995-12-20
ES2151544T3 (es) 2001-01-01
CA2152266A1 (en) 1994-07-07
DE69331813T4 (de) 2003-07-10
CN1089660A (zh) 1994-07-20
US6669946B2 (en) 2003-12-30
EP0687180A4 (de) 1998-01-07
DK1025849T5 (da) 2003-02-24
DK1025849T3 (da) 2002-05-21
AU5951794A (en) 1994-07-19
ES2172287T4 (es) 2003-04-16
FI953093L (fi) 1995-06-21
HK1031994A1 (en) 2001-07-06
PT1025849E (pt) 2002-09-30

Similar Documents

Publication Publication Date Title
ATE197403T1 (de) Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase- peptidantigenen exprimierenden zellen
ATE183514T1 (de) Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten
ATE294864T1 (de) Äusseres membranprotein von haemophilus
ATE196475T1 (de) Auf histatin basierende, gegen pilze und bakterien gerichtete peptide
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
ATE260295T1 (de) Peptidfragmente von mikrobiellen stressproteinen und daraus hergestellte pharmazeutische zusammensetzungen für die behandlung und vorbeugung von entzündungserkrankungen
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
DE69331813D1 (de) Verfahren zur Detektion und Behandlung von Individuen mit abnormal hla-a2/tyrosinase-peptidantigenen exprimierenden Zellen
ES2133813T3 (es) Cadenas de lamininas: diagnostico y uso terapeutico.
DE69840509D1 (de) Apoptose-bezogene verbindungen und deren verwendung
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
ATE193893T1 (de) Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t- lymphocyten und die diagnose des hcv-kontaktes
CA2351558A1 (en) Peptide fragments having cell death inhibitory activity
EA200300132A1 (ru) Стресс-белки и пептиды и способы их применения
DK0764273T3 (da) Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
FI963170A0 (fi) Menetelmä solujen poikkeavuudesta kärsivien yksilöiden tunnistamiseks i
DE69712182D1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
DE69531167D1 (de) Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen-karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen
PT854727E (pt) Antigenios de rejeicao tumoral apresentados pelas moleculas b44-alh e suas utilizacoes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee